Skip to content
MedsAcross

Molecule

Mupirocin

Also known as mupirocin calcium
Available on requestDermatology
Presentations
3
Brands
1
Manufacturers
1
Available from stock
0

Mupirocin is an RNA synthetase inhibitor antibacterial. It is available as ointment and cream for topical use. MedsAcross supplies Mupirocin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Key facts

Pharmacological class
RNA Synthetase Inhibitor Antibacterial, RNA Synthetase Inhibitors
ATC classification
D06AX09 Mupirocin · Antibiotics and antivirals for the skin, subgroup D06A, subgroup D06AXR01AX06 Mupirocin · Topical decongestant, subgroup R01AX
US FDA first approval
31 December 1987
EU status
Not recorded
Orphan designation
Not recorded
WHO essential medicine
Not recorded
India (CDSCO)
Not yet confirmed against CDSCO approval lists
Routes
Topical
Dosage forms
Ointment, Cream
Identifiers
UNII D0GX863OA5RxCUI 42372CAS 12650-69-0DrugBank DB00410Q413578

Clinical information

From the regulator-approved product information. Each section names its source.

Uses

Mupirocin cream is indicated for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm 2 in area) due to susceptible isolates of Staphylococcus aureus (S. aureus) and Streptococcus pyogenes (S. pyogenes). Mupirocin cream is an RNA synthetase inhibitor antibacterial indicated for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm 2 in area) due to susceptible isolates of Staphylococcus aureus and Streptococcus pyogenes. ( )

Source: US FDA prescribing information

Dosing overview

For Topical Use Only. Apply a small amount of mupirocin cream, with a cotton swab or gauze pad, to the affected area 3 times daily for 10 days. Cover the treated area with gauze dressing if desired. Re-evaluate patients not showing a clinical response within 3 days to 5 days. Mupirocin cream is not for intranasal, ophthalmic or other mucosal use. Do not apply mupirocin cream concurrently with any other lotions, creams or ointments. For Topical Use Only. Not for intranasal, ophthalmic or other mucosal use.

Source: US FDA prescribing information

Contraindications

Mupirocin cream is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin cream. Known hypersensitivity to mupirocin or any of the excipients of mupirocin cream.

Source: US FDA prescribing information

Warnings and precautions

Severe Allergic Reactions: Anaphylaxis, urticaria, angioedema and generalized rash have been reported in patients treated with formulations of mupirocin, including mupirocin cream. Eye Irritation: Avoid contact with eyes. Local Irritation: Discontinue in the event of sensitization or severe local irritation. Clostridium difficile -Associated Diarrhea (CDAD): If diarrhea occurs, evaluate patients for CDAD. Potential for Microbial Overgrowth: Prolonged use may result in overgrowth of nonsusceptible microorganisms, including fungi. Risk Associated with Mucosal Use: Mupirocin cream is not formulated for use on mucosal surfaces. A separate formulation, mupirocin nasal ointment, is available for intranasal use.

Source: US FDA prescribing information

Side effects

The following adverse reactions are discussed in more detail in other sections of the labeling: Severe Allergic Reactions Eye Irritation Local Irritation Clostridium difficile -Associated Diarrhea The most frequent adverse reactions (at least 1%) were headache, rash and nausea.

Source: US FDA prescribing information

Storage

Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F). Do not freeze.

Source: US FDA prescribing information

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

All presentations

3 presentations of Mupirocin, sorted by availability.

MedicineManufacturerRegisterAvailability
Mupirocin 2% ointmentTopicalGeneric name—US FDAAvailable on request
Mupirocin 2% creamTopicalGeneric name—US FDAAvailable on request
Pirnuo 2% creamTopicalGlenmark PharmaceuticalsIndiaUS FDAAvailable on request

Brands by market

1 brand names across 1 markets.

Brand names by country

United States

Manufacturers

Indian manufacturers are highlighted.

Regulatory status

Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.

RegisterStatusSource
US FDAFirst approved 31 December 1987Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Conditions

Conditions linked to Mupirocin in public data. This is not a list of approved uses, see the clinical information.

Questions and answers

Is Mupirocin available for export from India?

Yes, on request. MedsAcross lists 3 presentations of Mupirocin and sources them for licensed hospitals, importers and physicians against valid import documents. Indian manufacturers include Glenmark Pharmaceuticals.

What brand names does Mupirocin have?

The catalogue lists 1 brand names for Mupirocin, including Pirnuo.

Is Mupirocin approved by the US FDA?

Yes. The US FDA first approved Mupirocin on 31 December 1987, according to Drugs@FDA.

Does Mupirocin need cold chain shipping?

No listed presentation of Mupirocin is recorded as needing a cold chain. Storage conditions are shown on each presentation page.

Which ATC class is Mupirocin in?

Mupirocin is classified under ATC code D06AX09 (Mupirocin).

References

  1. Mupirocin prescribing information (Viona Pharmaceuticals). U.S. National Library of Medicine, DailyMed. Retrieved 1 October 2026

Request Mupirocin for export supply

Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.